200 related articles for article (PubMed ID: 1796407)
1. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.
Bevers EM; Galli M; Barbui T; Comfurius P; Zwaal RF
Thromb Haemost; 1991 Dec; 66(6):629-32. PubMed ID: 1796407
[TBL] [Abstract][Full Text] [Related]
2. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
[TBL] [Abstract][Full Text] [Related]
3. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies.
Galli M; Beretta G; Daldossi M; Bevers EM; Barbui T
Thromb Haemost; 1997 Mar; 77(3):486-91. PubMed ID: 9065999
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies.
Galli M; Comfurius P; Barbui T; Zwaal RF; Bevers EM
Thromb Haemost; 1992 Sep; 68(3):297-300. PubMed ID: 1440495
[TBL] [Abstract][Full Text] [Related]
5. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies.
Galli M; Finazzi G; Bevers EM; Barbui T
Blood; 1995 Jul; 86(2):617-23. PubMed ID: 7605991
[TBL] [Abstract][Full Text] [Related]
6. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.
Takeya H; Mori T; Gabazza EC; Kuroda K; Deguchi H; Matsuura E; Ichikawa K; Koike T; Suzuki K
J Clin Invest; 1997 May; 99(9):2260-8. PubMed ID: 9151800
[TBL] [Abstract][Full Text] [Related]
7. Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin.
Rao LV; Hoang AD; Rapaport SI
Thromb Haemost; 1995 Apr; 73(4):668-74. PubMed ID: 7495076
[TBL] [Abstract][Full Text] [Related]
8. [Lupus anticoagulants versus antiphospholipid antibodies].
Pereira MI
Acta Med Port; 1998 Apr; 11(4):349-57. PubMed ID: 9644846
[TBL] [Abstract][Full Text] [Related]
9. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.
Galli M; Dlott J; Norbis F; Ruggeri L; Cler L; Triplett DA; Barbui T
Thromb Haemost; 2000 Dec; 84(6):1012-6. PubMed ID: 11154107
[TBL] [Abstract][Full Text] [Related]
10. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
Monteiro RQ; Zingali RB
Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
[TBL] [Abstract][Full Text] [Related]
11. Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper venom time for verification of lupus anticoagulants.
Alving BM; Barr CF; Johansen LE; Tang DB
Thromb Haemost; 1992 Jun; 67(6):672-8. PubMed ID: 1509408
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin.
Rauch J; Tannenbaum M; Neville C; Fortin PR
Thromb Haemost; 1998 Dec; 80(6):936-41. PubMed ID: 9869164
[TBL] [Abstract][Full Text] [Related]
13. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
14. Detection of procoagulant phospholipid interfering in tests for lupus anticoagulant.
Exner T; Low J
Thromb Res; 2004; 114(5-6):547-52. PubMed ID: 15507290
[TBL] [Abstract][Full Text] [Related]
15. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid.
Rao LV; Hoang AD; Rapaport SI
Blood; 1996 Dec; 88(11):4173-82. PubMed ID: 8943852
[TBL] [Abstract][Full Text] [Related]
17. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles.
Galli M; Bevers EM; Comfurius P; Barbui T; Zwaal RF
Br J Haematol; 1993 Mar; 83(3):466-72. PubMed ID: 8485053
[TBL] [Abstract][Full Text] [Related]
18. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I.
Arnout J; Meijer P; Vermylen J
Thromb Haemost; 1999 Jun; 81(6):929-34. PubMed ID: 10404770
[TBL] [Abstract][Full Text] [Related]
19. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies.
Pengo V; Biasiolo A; Rampazzo P; Brocco T
Thromb Haemost; 1999 Feb; 81(2):256-8. PubMed ID: 10064002
[TBL] [Abstract][Full Text] [Related]
20. [Assay principles of antiphospholipid antibodies and heterogeneity of the antibodies].
Matsuura E
Rinsho Byori; 2000 Apr; 48(4):317-22. PubMed ID: 10810876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
